



SPANISH BIOINDUSTRY ASSOCIATION PAVILION
BIO-EUROPE 2019
NOVEMBER 11-13, 2019
HAMBURG, GERMANY

biospain

2020

10th International Meeting on Biotechnology
September 29th – October 1st, 2020
Pamplona, Spain



+750 licensing opportunities



54 investors



1.550 attendees



3.330 one-to-one meetings



200 exhibitors



31 countries represented



+40 sessions



**3rd largest biotech
partnering event in Europe**

www.biospain2020.org

ORGANIZED BY:

asebio
Spanish Bioindustry Association

Nafarroako
Gobernua



Gobierno
de Navarra

SODENA
DESARROLLO DE NAVARRA
NAFARROAKO GARAPENA

3P BIOPHARMACEUTICALS

CDMO specializing in the process development and GMP manufacturing of biologics as well as cell therapy products using microbial and mammalian expression systems. Services:

- Cell line development
- Cell bank cGMP manufacturing and characterization
- Analytical methods development, qualification, and validation
- Scale-up and cGMP supply for clinical trials
- Process characterization & validation
- Commercial supply
- Drug Substance and Drug Product testing and release
- Drug Substance and Drug Product stability studies
- Formulation development
- Comparability studies
- Reference standard manufacturing
- Fill and Finish for DP (with partners)



 *Dámaso Molero, CEO*
 *businessdevelopment@3pbio.com*
 *www.3pbio.com*
 *Polígono Mocholi*
C/Mocholi 2, 31110 Noáin, (Navarra) Spain
 *www.linkedin.com/company/3p-biopharmaceuticals/*
 *@3PBio*

53BIOLOGICS

53Biologics is a contract development and manufacturing organization with extensive experience in cell lines development, bioprocess development and scale-up, and recombinant protein batches production.

Cell line development: 53Biologics has proven experience producing a broad catalog of recombinant proteins (monoclonal, fusion, chimeric and fragment antibodies, biosimilars, enzymes, anticoagulants, vaccines...) in a wide range of microbial expression systems such as yeast, fungi or bacteria, mammalian expression systems and insect cells.

Process development: we are experts in the optimization of the production process, product recovery and purification, ready to be transferred for manufacturing.

Analytics: 53Biologics can implement and validate the analytic methods needed for the characterization of the protein of interest.

Contract productions: The company offers very a high production flexibility, making possible the production of recombinant protein batches at different fermentation volumes, with a high ability to adapt to the method transferred by the client and always meeting the agreed deadlines.

The logo for 53Biologics, featuring the number '53' in a stylized blue font followed by the word 'Biologics' in a blue sans-serif font.

Carmen Martinez Rodríguez, BD Manager



cmartinez@53biologics.com



www.53biologics.com



Boecillo Technological Park.

13 Louis Proust Street, 47151 Valladolid, Spain



www.linkedin.com/company/53biologics



[@53Biologics](https://twitter.com/53Biologics)

ABILITY PHARMACEUTICALS

AbilityPharma is a clinical-stage biopharmaceutical company focused on developing first-in-class anticancer compounds causing autophagy via the inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress).

The first drug candidate ABTL0812 is currently in phase 2 clinical trials as first-line therapy for endometrial cancer and for squamous NSCLC in combination with chemotherapy, followed by maintenance as single-agent. Results for the endometrial cancer group are already available and very promising. The study includes leading institutions in Spain and France. The investigational new drug (IND) is also approved in the US by the FDA with clinical trials protocols approved in endometrial, lung and pancreatic cancer, and in China for pancreatic cancer.

ABTL0812 is licensed to SciClone Pharmaceuticals for greater China. The company is currently seeking to license for the rest of the world or in selected regions.




 **Maribel Berges, CEO**
 **contact@abilitypharma.com**
 **www.abilitypharma.com**
 **Avinguda Parc Tecnològic, 3**
08290 Cerdanyola (Barcelona), Spain
 **[@AbilityPharma](https://www.facebook.com/AbilityPharma)**
 **www.linkedin.com/company/abilitypharma**
 **[@AbilityPharma](https://twitter.com/AbilityPharma)**

ADVANCED MARKER DISCOVERY

Founded in 2010, Amadix is a leading molecular diagnostics company focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. The mission of the company is saving lives, developing disruptive technologies to detect the tumor years in advance, before the symptoms appear, to win the battle against cancer and extend people lives.

The company's products are oriented to non-invasive early cancer detection, avoiding the complications of existing invasive procedures, as tumor biopsies.

ColoFast, the most advanced product is an innovative blood-based test for colorectal cancer diagnosis based on a unique combination of cutting-edge biomarkers, which have never been used in CRC as of today. It is indicated to screen healthy population 50 to 85 years old, for early detection of the tumour and premalignant lesions. ColoFast is expected to be commercialized in 2020. The Company's test pipeline includes two blood-based tests for early detection of lung and pancreatic cancer.



 *Rocio Arroyo, CEO*
 *info@amadix.com*
 *www.amadix.com*
 *Acera de Recoletos 2,1ºB, 47004 Valladolid, Spain*
 *[@AmadixDx](https://www.facebook.com/AmadixDx)*
 *www.linkedin.com/mwlite/company/amadix*
 *[@AmadixDx](https://twitter.com/AmadixDx)*

ANAPHARM BIOANALYTICS

Anapharm Bioanalytics is a bioanalytical contract research organisation (CRO) based in Barcelona, providing support to the pharmaceutical, biopharmaceutical and generic industries globally, with a focus on full-service bioequivalence studies, as well as high-quality bioanalytical services for small and large molecule sample analysis in Phase I-II-III trials and non-clinical studies in compliance with EMA, FDA & ANVISA regulations.

Anapharm has highly trained scientists with over 30 years of experience in the industry. More than 1,500 bioequivalence studies have been performed and over 500 bioanalytical methods are available.

In addition, the firm has undergone 20 inspections from regulatory authorities: 14 studies inspected by FDA (US), 12 studies inspected by EU-GCP authorities and several inspections for GLP certification by EU authorities and ANVISA (Brasil). Such inspections grant its robust regulatory track record, ensuring delivery of consistent, reproducible and reliable data required for international registration.



 *Robert Fontarnau, Business Development Director*
 *contact@anapharmbioanalytics.com*
 *www.anapharmbioanalytics.com*
 *Encuny 22, 2nd floor, 08038 Barcelona, Spain*
 *[@Anapharm Bioanalytics](https://www.linkedin.com/company/anapharm-bioanalytics)*

ARRAYS FOR CELL NANODEVICES

A4CELL presents a New technology named SPACHip (Suspended Planar-Array Chips) brings you a perfect way to monitorize single cell alive. SPACHips are intracellular silicon microchips for monitoring extraordinarily small volumes as a single cell.

Microarray technology, but NOW in a single cell alive! SPACHip device that can be easily internalized in alive cells without affecting cell viability or inducing physiological changes

SPACHip are silicon-based planar chips small enough to reach cell cytoplasm.

Its surface is functionalized by microcontact printing, making them the first intracellular device that can be multiplexed with probes emitting in the same wavelength.



Elena Rivas, CEO



elena.rivas@a4cell.com



Génova 11, 28004 Madrid, Spain

ASCIL PROYECTOS

ASCIL Biopharm develops proprietary miniaturized injectable and locally acting therapeutics with advanced drug delivery systems (DDS) - formulations and medical devices - to enhance the safety, effectiveness and convenience of administration of drugs for chronic high burden diseases. The company's approach leverages the expertise of its highly experienced team, which has pioneered the development of commercial controlled release peptide therapeutics, including long-acting biodegradable and self-assembly DDS.

ASCIL has proprietary products for licensing or co-development and collaborates with companies and institutions to apply its DDS expertise to their compounds. The company has a portfolio of clinical-ready products for licensing and a pipeline of preclinical stage products for co-development or licensing.



 *Tabatha Bourgois, MedTech Project Manager*
 *busdev@ascil-biopharm.com*
 *www.ascil-biopharm.com*
 *Cami de les Filipines 110*
08840 Viladecans (Barcelona), Spain
 *www.linkedin.com/company/ascil-biopharm*
 *@AscilBiopharm*

ASEBIO – SPANISH BIOINDUSTRY ASSOCIATION

Asebio, the Spanish Bioindustry Association, aspires to lead the transformation of our country, Spain, positioning innovation as the engine of its competitiveness and social development, thus promoting the development of the biotechnological ecosystem as a key element of this paradigm shift. We work to achieve an optimal legal, political and economic environment for the biotechnology industry and act as a catalyst for the innovation opportunities offered by biotechnology.

With over 280 members, Asebio is one of the largest biotechnology associations in Europe and the organizer of the main industry events in Spain such as BioSpain & Asebio Investor Day.



-  *David Fernández, BD & International Affairs Manager*
-  *Esther Campos, BD & International Affairs Coordinator*
-  *secretariageneral@asebio.com*
-  *www.asebio.com*
-  *C/ Diego de León 49, 1º Izq., 28006 Madrid, Spain*
-  *[@asebio.biotechnologia](https://www.facebook.com/asebio.biotechnologia)*
-  *www.linkedin.com/company/asociacion-espanola-de-bioempresas*
-  *[@asebio](https://twitter.com/asebio)*
-  *[@asebio](https://www.instagram.com/asebio)*

ASPHALION

Asphalion is an international Scientific and Regulatory Affairs consultancy, with offices in Barcelona, Madrid, Munich and Amsterdam.

We collaborate with Pharma and Biotech companies facilitating Drug Development and Regulatory Affairs projects for Drugs, Biologics, Biosimilars, ATMPs and Medical Devices. Our involvement ranges from early development, through to registration and post-commercialization phases.

Since the company was founded in 2000, we have consistently grown and now have a team of over 90 employees with backgrounds in all areas of life sciences.

Our consultants are experts in their fields and are in direct contact with European agencies for the implementation of new regulatory standards.

Through collaborations with partners in all other continents, we can accelerate your world-wide scientific and regulatory activities. Services:

- Regulatory and Scientific Strategy during Development
- Medical and Scientific Writing
- Global Submissions
- eSubmission and RIM
- Life-Cycle Outsourcing
- Pharmacovigilance
- Promoting the marketing registration of Medical Devices:
Classification strategy, CE Marking and compilation of technical file.



Lidia Cánovas, General Manager Regulatory Affairs



info@asphalion.com



www.asphalion.com



C/ Tarragona, 151 - 157, 08014 Barcelona, Spain



www.linkedin.com/company/asphalion



[@asphalion](https://twitter.com/asphalion)

BIOCAT, LA FUNDACIÓ BIOREGIÓ DE CATALUNYA

Biocat is the organization that champions the Healthcare and Life Sciences ecosystem in Catalonia, the most dynamic BioRegion in Spain.

Biocat focuses its strategy on different key points:

- Grow Innovation & Accelerate Business
- Develop Talent & Boost Knowledge
- Position BioRegion Internationally

Set up in 2006 as a public/private foundation, Biocat -along with the government- also drives strategic wide-range policies and projects aimed towards contributing the competitiveness of the sector.



Jordi Naval, CEO



arovira@biocat.cat



www.biocat.cat



*Baldiri Reixac, 4-8, Torre I (PCB)
08028 Barcelona, Spain*



www.linkedin.com/company/703143/admin



@biocat_en

BIOFABRI

BIOFABRI is a CDMO. Focused on Human health, which holds EU GMP certification.

Biofabri is an ideal partner for any organization intending to advance their biologic product candidates from development scale to clinical Phase I to III, and commercial supplies capability – Under construction- (Clinical material manufacturing, Aseptic filling, Lyophilization, Labeling-Packaging and Storage)

State-of-art technology, with strong technical, development and manufacturing capabilities and a proven track record.

BIOFABRI is a company of ZENDAL Group (www.zendal.com). Focus on Biotechnology and is engaged in the development, manufacturing and marketing of biological and pharmaceutical products for human and animal health.

- cGMP Master and Working Seed Lots of cells, Virus and Bacteria.
- GMP Upstream & Downstream processes.
- Wide capacity for aseptic filling.
- Lyophilization
- Vaccines formulation.
- cGMP manufacture of batches for clinical Trails.
- Stability testing of seed lots, intermediates and finished products. In-use stability studies.
- Packaging.
- Biological and sterile products release.
- GDP Authorization: Storage and Shipment.



Mercedes Rodríguez Rojas, Business Manager



mercedes.rodriguez@biofabri.es



www.biofabri.es



A Relva s/n., 36400 O Porriño (Pontevedra), Spain



www.linkedin.com/company/2145255/admin

BIOINGENIUM

BIOINGENIUM is a CDMO company located in Barcelona that provides recombinant protein production services for biotech and pharma.

BIOINGENIUM is one of the world specialists in PICHIA PASTORIS, we provide a freedom-to-operate system in combination with strain engineering and proprietary UPSTREAM and DOWNSTREAM processes. We are experts in taking your proteins from the laboratory bench to production scale of grams of protein with the highest quality.

Bioingenium is a flexible and expert partner that makes affordable the path to success of your protein.



 *David Resina, CEO*
 *info@bioingenium.net*
 *www.bioingenium.net*
 *Barcelona Science Park.*
Baldiri Reixac 15, 08028 Barcelona, Spain
 *www.linkedin.com/company/bioingenium-s-l*
 *@bioingenium*

BIONURE FARMA

An optimal candidate to treat neurodegenerative diseases like multiple sclerosis: this is Bionure's goal with its first drug: BN201. After proving it can protect neurons and promote remyelination in model animal, the molecule has completed phase 1 trial in United Kingdom in 48 healthy volunteers. Bionure hopes to launch phase 2 trials in early 2020 to prove the efficacy of BN201 in patients who suffers from acute episodes of optic neuritis. The company is currently focusing its efforts on multiple sclerosis and acute optic neuropathy, a rare ophthalmologic disease for which BN201 is designated an orphan drug in Europe and the United States. A Spin-off of IDIBAPS and CISC, Bionure was founded in 2009 and is based in Barcelona Science Park. Late 2017, the company welcomed a first institutional VC investor, Alta Life Science, which led a Series A round to finance a first clinical phase 1 study recently closed an internal round and a second crowdfunding round to find regulatory and technical preparations for the next step for the next step: phase 2 study.

bionure
Promoting Neuroprotection



Laurent Nguyen, CEO



lfontana@bionure.com



www.Bionure.com



Parc Científic de Barcelona

C/ Baldori i Reixac, 4-8, 08028 Barcelona, Spain



[@Bionure](https://www.facebook.com/Bionure)



www.linkedin.com/company/bionure



[@Bionure](https://twitter.com/Bionure)

CHARLES RIVER LABORATORIES

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.

Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

From research models all the way through the GMP release of your biopharmaceutical product, Charles River supports your drug development. Every step of the way.

- Research Models and Services
- Discovery Services
- Safety Assessment
- Microbial Solutions
- Biologics Testing Solutions



 *Luis Berrade, Associate Director BD Europe*
 *Björn Kolbe, Sr. BD Specialist*
 *askcharlesriver@crl.com*
 *www.criver.com*
 *251 Ballardvale St, Wilmington,
MA 01887, United States*
 *www.linkedin.com/company/charles-river-laboratories*

ENTRECHEM

3 drugs in oncology: EC-8042, a first in class transcription reprogramming agent for tumors with genomic instability, including pediatric indications (Ewing, rhabdoid); EC-70124 a next-generation multi-kinase inhibitor, first in class triple FLT3-PIM-SYK inhibitor for AML; and EC-7072, a transcription modulator for CLL independent of mutational status and interphase cytogenetics.



Francisco Moris, Managing Director



info@entrechem.com



www.entrechem.com



*Vivero Ciencias de la Salud,
Calle Colegio Santo Domingo Guzmán
33011 Oviedo, Spain*

LABORATORIOS RUBIÓ

Laboratorios Rubio is a family owned healthcare laboratory specialiced in medicines, IVD and some nutraceuticals for low prevalence pathologies in the fields of Rheumatology, Cardiovascular, Nephrology, Urology and CNS. Through its international network of partners already exports to 47 countries with 13 more with products in registration. Recent Launchings: LIPOSCALE (ce) an IVD to improve the assesement of cardiovascular risk amd Rubidiet Nefro a food for special medical purpose for patients with CKD.

We are interested in licensing out our products to ROW and licensing in pharma, medical devices and IVD for Spain and LATAM.

More info in our profile for this event and our web page



 *Carlos Rubio, Executive President*
 *labrubio@labrubio.com | crubiob@labrubio.com*
 *www.laboratoriosrubio.com*
 *Calle Industria 29, Pol. Ind. Comte de Sert
08755 Castellbisbal, Barcelona, Spain*

LIM GLOBAL CONSULTING

LIM global are Life Science experts. From C-level to experienced managers we know and inspire the executives you need. LIM offers excellence in Executive Search, Interim Management and Consulting services for the biomedical industry.



Michael Thiele, Managing Director



limglobal@limglobal.com



www.limglobal.com



Beethoven 15 - 3 - 1, 08021 Barcelona, Spain



www.linkedin.com/company/lim-global-consulting-s.l



[@LIMExecSearch](https://twitter.com/LIMExecSearch)

MABXIENCE RESEARCH

Spanish fully-fledged biotech company, with a decade of experience in developing and manufacturing biosimilars.

- Part of the Spanish multinational Insud Pharma, which boasts over 40 years' experience and has +6,000 professionals based in 40 countries around the world.
- Portfolio with two biosimilar products in the market.
- Various biosimilar development programs underway to be marketed worldwide targeting the areas of hematology, oncology, osteoporosis and pediatrics.
- Global Partnership Network of key market leaders in the EU, US, Japan and Emerging Markets.
- Two Large-Scale Commercial Manufacturing Facilities in Spain and Argentina.



 *Ferran Garcia, Strategy & BD Associate Director*
 *ferran.garcia@mabxience.com*
ariana.menendez@mabxience.com
 *mabxience.com*
 *C/ Manuel Pombo Angulo, 28 3ª planta*
28050 Madrid, Spain
 *www.linkedin.com/company/mabxience*
 *[@mAbxience](https://twitter.com/mAbxience)*

MINORYX THERAPEUTICS

Minoryx Therapeutics S.L is a late clinical stage biotech company focused on the development of new therapies for X-ALD, Friedreich's Ataxia and other orphan CNS diseases, a group of rare diseases with high unmet medical need. The company's lead program, a differentiated PPAR gamma agonist (leriglitzone; MIN-102) that has applicability in multiple CNS indications, has successfully completed a phase 1 clinical trial and has now completed recruitment in a pivotal phase 2/3 trial for adult X-ALD patients (AMN) and in a phase 2 for Friedreich's Ataxia. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has operations both in Spain and Belgium. It has raised a total of €50M



 *Marc Martinell, CEO*
 *info@minoryx.com*
 *www.minoryx.com*
 *Av. Ernest Lluch 32,
08302 Mataró (Barcelona), Spain*

ORYZON GENOMICS

Oryzon is a public clinical stage biopharmaceutical company, leader in the development of epigenetics-based therapies with three programs:

- Vafidemstat (ORY-2001), a CNS optimized LSD1 inhibitor, with four ongoing Phase IIA trials: "ETHERAL", in mild to moderate AD; "REIMAGINE", aggressiveness in ADHD, BPD and ASD; "REIMAGINE-AD", aggressiveness in moderate to severe AD; and "SA-TEEN", in RRMS and SPMS.
- Iadademstat (ORY-1001), a selective LSD1 inhibitor, with two ongoing Phase IIA trials: "ALICE": in AML and "CLEPSIDRA": in ED-SCLC.
- ORY-3001, a third epigenetic compound, also against LSD1. It is ready to start Phase I in a yet undisclosed indication.



Carlos Buesa Arjol, CEO



cbuesa@oryzon.com



www.oryzon.com



C/ Sant Ferrán, 74.

08940 Cornellà de Llobregat (Barcelona), Spain

PEPTOMYC

Peptomyc technology and IP is founded on the knowledge accumulated by Dr. Soucek's lab on Omomyc, a dominant-negative Myc mutant that is the most efficacious and safe direct Myc inhibitor to date and that shows great therapeutic promise in a variety -if not all- cancer types. Omomyc was considered a proof of principle for many years, and its application was to be limited to gene therapy. However, Dr. Soucek's lab has shown that the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cells. Peptomyc now aims to further develop the Omomyc peptide – and improved variants – into clinically viable therapeutics for the treatment of cancer patients. First clinical trials in lung and breast cancer patients are planned in 2020.



Laura Soucek, CEO



info@peptomyc.com



www.peptomyc.com



[Carrer de Natzarret, 115, Barcelona 08035, Spain](#)



www.linkedin.com/company/peptomyc

PHARMA MAR

PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development, which takes inspiration from the sea to discover molecules with antitumor activity. It is an integrated company that seeks innovative products to provide health-care professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. With subsidiaries in Europe and the United States, PharmaMar develops and commercializes Yondelis® in Europe, along with Aplidin®, approved for the Australian market, also having other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14.

PharmaMar fully owns other companies. GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi).



-  *Heiner Pieper,*
Vice President Business Development & Licensing
-  *bdevelopment@pharmamar.com*
-  *www.pharmamar.com*
-  *Avda. de los Reyes, 1 -*
28770 Colmenar Viejo (Madrid), Spain
-  *@PharmaMarES*
-  *es.linkedin.com/company/pharmamar*
-  *@PhrmMar*
-  *@pharmamar*
-  *www.youtube.com/c/pharmamar_official*

SABADELL ASABYS HEALTH INNOVATION INVESTMENTS

Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies. Asabys started operations in 2019 and is currently fundraising its first fund, Sabadell Asabys Health Innovation Investments, with a target size of €75M, with the participation of Banc Sabadell as anchor investor in their strategy to promote the health-care innovation entrepreneurial ecosystem.



Clara Campàs, Partner



info@asabys.com



www.asabys.com



Paseo de Gracia, 53 Àtico, 08007 Barcelona, Spain



es.linkedin.com/company/asabys-partners



[@asabyspartners](https://twitter.com/asabyspartners)



www.instagram.com/asabyspartners

SANIFIT THERAPEUTICS

Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, with SNF472 as its lead compound. The company started activities in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Spain and the USA.

Sanifit's lead compound is SNF472, a novel small molecule that is a selective and potent inhibitor of hydroxyapatite crystallisation, the final common pathway that leads to vascular calcification. SNF472 is in clinical development for the treatment of calciphylaxis (CUA) in patients undergoing dialysis. In 2018 Sanifit completed a phase II proof-of-concept trial in patients with CUA, which met its primary and secondary endpoints and a phase 3 pivotal study is in preparation. The company is also investigating SNF472 in a Phase 2b proof of concept study (CaLIPSO) to assess its effect on the reduction of cardiovascular calcification progression, with results expected in Q4 2019.



 *Joan Perelló, CEO*
 *info@sanifit.com*
 *www.sanifit.com*
 *ParcBIT. Edificio Europa. 2º piso.*
Ctra Valldemossa km 7.4, 07121 Palma, Spain
 *es.linkedin.com/company/sanifit-laboratoris*
 *@SanifitLabs*

SOM BIOTECH

SOM Biotech is a clinical-stage med-tech company focused on Accelerated discovery of the therapies for Neurological Orphan indications. We use the unique approach based on our Computational Artificial Intelligence-based Platform and Scientific Expertise of our Team.

We apply this approach for:

Proprietary pipeline:

- Asset for TTR-Amyloidosis was licensed to a world-wide company based in NY after Phase 2a
- Huntington/Tardive Dyskinesia - Phase 2a finished
- Adrenoleukodystrophy - ready for Phase 2a
- Phenylketonuria and Niemann-Pick - Pre-clinical
- More than 15 compounds - early stage

Our partners, to help them with:

- Identification of new indications for their drugs for life cycle management;
- Identification of effective drugs within any therapeutic area for Pipeline expansion.



 *Raül Insa, Founder, President and CEO*
 *zimina@sombiotech.com*
 *www.sombiotech.com*
 *Carrer de Baldri Reixac, 4*
08028 Barcelona, Spain
 *www.linkedin.com/company/2354325*
 *@sombiotech*

VIVEBIOTECH

VIVEbiotech is a company fully specialized in lentiviral vectors.

As a GMP Contract Development and Manufacturing Organization (CDMO), we are specialized in lentiviral vector bioprocess development (from very early stages) and GMP manufacturing. VIVEbiotech has experience in manufacturing lentiviral vectors for different applications such as cancer immune-cell therapy projects (CAR-Ts/TCRs...) and rare diseases, among others.

Currently, we are manufacturing lentiviral vectors for Europe, US and Australia being highly flexible in terms of technical adaptation.

Additionally, VIVEbiotech is working on improved producer cell line development, new pseudo-typing strategies and the development of its own worldwide licensed technology: a non-integrative episomal stable lentiviral vector (LENTISOMA).



 *Natalia Elizalde, Business Development Director*
 *info@vivebiotech.com*
 *www.vivebiotech.com*
 *Paseo Mikeletegi 81,
Parque Científico y Tecnológico de Gipuzkoa
20009 San Sebastián, Gipuzkoa, Spain*
 *www.linkedin.com/company/vivebiotech*

VIVOTECNIA RESEARCH

Vivotecnia is a fully independent European toxicology safety contract research organization (CRO) with headquarters based in Madrid, Spain. Our lab was founded in 2000. We offer services to support preclinical product development for pharmaceutical and biotech companies and product safety studies for the cosmetic, chemical and agrochemical, food and tobacco industries from around the world.

Our state-of-the-art facilities are GLP-accredited, and the company is managed under the ISO 9001:2008 system. Vivotecnia relies on a strong process-driven environment focused on achieving the highest quality standards on tight deadlines and at competitive prices.

Our design and implementation of state-of-the-art information technologies further enhance performance and delivery. Our animal units house rodents, dogs, rabbits, minipigs and nonhuman primates. Our highly qualified study management team, with lengthy experience in both pharmaceutical and CRO industries, fully understands the challenges you face and is committed to providing the knowledge, advice and high-quality service you expect.



 *Jonatan Rapaport, Business Development Manager*
 *bd@vivotecnia.com*
 *www.vivotecnia.com*
 *Parque Científico de Madrid, PTM
C/ Santiago Grisolia, 2.
28760 Tres Cantos, Madrid, Spain*
 *www.facebook.com/vivotecnia*
 *www.linkedin.com/company/2639067*
 *[@Vivotecnia](https://twitter.com/Vivotecnia)*



asebio

Spanish Bioindustry Association

Diego de León, nº 49, 1º Izqda.

28006 MADRID (Spain)

Tels: +34 91 210 93 10 / 74

www.asebio.com